Employers continue to face significant challenges as they strive to provide healthcare coverage for their employees during the COVID-19 pandemic. In this discussion, moderated by Burt Zweigenhaft, PhD, D.Litt, a panel of experts explore solutions for some of the issues arising in a vastly changed healthcare market, and strategies for improving the way in which health benefits are conceived and implemented.
Opdivo-Yervoy First Immunotherapy Combo Approved for First-Line Therapy of Patients with Metastatic NSCLC
On May 15, 2020, the FDA approved a new indication for the first immunotherapy combination with the PD-1 inhibitor nivolumab (Opdivo; BMS) and the CTLA-4 inhibitor ipilimumab (Yervoy; BMS) as first-line treatment of adults with metastatic non–small-cell lung cancer (NSCLC) and PD-L1 expression of ≥1%, as determined by an FDA-approved test, but without EGFR or ALK genomic alterations.
On May 6, 2020, the FDA accelerated the approval of oral capmatinib (Tabrecta; Novartis), a kinase inhibitor, for the treatment of adults with metastatic non–small-cell lung cancer (NSCLC). Capmatinib is the first agent approved by the FDA for metastatic NSCLC with mutations that lead to MET exon 14 skipping, as determined by the FoundationOne CDx assay, which is approved as a companion diagnostic for capmatinib.
On May 8, 2020, the FDA approved selpercatinib (Retevmo; Loxo Oncology) capsules for the treatment of 3 types of cancer associated with RET gene mutations or fusions, including (1) metastatic non–small-cell lung cancer, (2) metastatic medullary thyroid cancer, and (3) other types of thyroid cancers. Selpercatinib is the first therapy approved for patients with cancer that is linked to RET mutations.
Pharmaceutical support and innovation are vital to the effective treatment of patients with cancer. In this discussion, moderated by Burt Zweigenhaft, PhD, D.Litt, a panel of experts discussed the importance of maintaining an adequate supply of medicines for patients, and the need for philanthropic programs to ensure patients will be able to continue their medications, even if they lose their health insurance.
In this discussion, moderated by Niesha Griffith, RPh, MS, FASHP, CPO (interim), a panel of oncology pharmacists discuss the impact of the COVID-19 pandemic on their practices, the increase in the use of new technologies as a result of recent events, and how the influx of patients expected in the coming weeks will affect their daily operations.
Large community care centers remain committed to providing necessary treatment to patients with cancer during the COVID-19 pandemic. In this discussion, moderated by Ted Okon, MBA, a panel of experts discuss the ongoing challenges that oncology providers face as they navigate an evolving healthcare ecosystem, and provide valuable insights on how practices may continue to deliver care in the months ahead.
As a result of the ongoing COVID-19 pandemic, comprehensive cancer care centers have been tasked with significantly altering their strategies for the delivery of care. In this discussion, moderated by Burt Zweigenhaft, PhD, D.Litt, a panel of experts discuss some of the changes that have already been implemented at their centers and future considerations for healthcare systems as they focus on providing safe and effective care on the road to recovery.
Issues surrounding healthcare insurance continue to unfold in light of the recent COVID-19 pandemic. In this discussion, a panel of managed care experts, moderated by Michael Kolodziej, MD, explore strategies for reducing the total cost of care for patients with cancer and addressing the economic and administrative burdens that practices and payers are facing as a result of the crisis.
Addressing the significant physical and psychosocial needs of patients with cancer during the COVID-19 crisis remains a top priority for healthcare providers. In this discussion, moderated by Elizabeth Franklin, PhD, MSW, a panel of specialists explore efforts underway to advocate for patients who are coping with stress, anxiety, and various economic burdens.
Page 4 of 32
Results 31 - 40 of 314
Results 31 - 40 of 314